Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation EuroPCR 2022

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Presenter: Ajay J. Kirtane, Michel Azizi

May 17, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Presentation TCT Abstracts Posters 2018

Impact of HDL to major adverse limb event in end-stage renal disease on hemodialysis due to diabetic nephropathy. from PREDICT study

Presenter: Tamon Kato

September 25, 2018

Presentation JIM 2018

Vascular Complications

Presenter: Bernhard Reimers

February 23, 2018

Presentation

Death and Dialysis After TAVR:Analysis of STS/ACC TVT Registry

October 17, 2017

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

Presentation TVT 2016

Severe Chronic Kidney Disease and TAVR: Clinical Management Recommendations

Presenter: Ganesh Manoharan

June 17, 2016

Presentation SOLACI 2016

Denervación Renal - Donde estamos hoy?

Presenter: Humberto Casal Pati?o

June 10, 2016

Presentation

Prevention of Contrast-Induced Nephropathy by Central Venous Pressure (CVP)-Guided Fluid Administration

Presenter: G. Qian

December 08, 2015

Presentation

Representation of Patients With Kidney Disease in Trials of CVD Interventions

Presenter: Ioannis Konstantinidis

December 02, 2015

Presentation

AKI in Patients With Chronic Kidney Disease Undergoing Internal CAS Implantation

Presenter: M. Donahue

September 25, 2015

Presentation

PROTECT-TAVI: AKI With the RenalGuard System in Patients Undergoing TAVR

Presenter: Marco Barbanti

September 21, 2015

Presentation

Incidence and Predictors of Early and Midterm Clinically Relevant Neurological Events After TAVR

Presenter: Johan Bosmans

July 14, 2015

Presentation

Choice of eGFR Equation Impacts Drug-Dosing Recommendations and Risk Stratification in CKD Patients Undergoing PCI

Presenter: J. Parsh

June 26, 2015

Presentation TCT 2014

Case Presentation: A Complex Patient at High Risk for Contrast-Induced Nephropathy

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon, Graham A. Cassel

September 16, 2014

Presentation TCT 2014

Access Site and the Risk of Acute Kidney Injury

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon, Hitinder S. Gurm

September 16, 2014

Presentation TCT 2014

Clinical Trial Updates: RenalGuard, AVERT, etc.

Presenter: Antonio L. Bartorelli, Somjot S. Brar, Roxana Mehran, Richard Solomon

September 16, 2014

Presentation TCT 2014

Very Low Intravenous Contrast Dose (20cc) Protocol for Computed Tomography Angiography (CTA) Providing Comprehensive Cardiac and Vascular Assessment for Transcatheter Aortic Val___

Presenter: Todd Pulerwitz

September 16, 2014

Advertisement

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Current Status and Future of Renal Denervation for Hypertension

Impact of HDL to major adverse limb event in end-stage renal disease on hemodialysis due to diabetic nephropathy. from PREDICT study

Vascular Complications

Death and Dialysis After TAVR:Analysis of STS/ACC TVT Registry

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

Severe Chronic Kidney Disease and TAVR: Clinical Management Recommendations

Denervación Renal - Donde estamos hoy?

Prevention of Contrast-Induced Nephropathy by Central Venous Pressure (CVP)-Guided Fluid Administration

Representation of Patients With Kidney Disease in Trials of CVD Interventions

AKI in Patients With Chronic Kidney Disease Undergoing Internal CAS Implantation

PROTECT-TAVI: AKI With the RenalGuard System in Patients Undergoing TAVR

Incidence and Predictors of Early and Midterm Clinically Relevant Neurological Events After TAVR

Choice of eGFR Equation Impacts Drug-Dosing Recommendations and Risk Stratification in CKD Patients Undergoing PCI

Case Presentation: A Complex Patient at High Risk for Contrast-Induced Nephropathy

Access Site and the Risk of Acute Kidney Injury

Clinical Trial Updates: RenalGuard, AVERT, etc.

Very Low Intravenous Contrast Dose (20cc) Protocol for Computed Tomography Angiography (CTA) Providing Comprehensive Cardiac and Vascular Assessment for Transcatheter Aortic Val___

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content